May 23, 2026
Last updated: May 23, 2026 · By Compliance Carl, Senior Compliance Editor
Jane is a Massachusetts medical marijuana patient. She has a state-issued card, a 3.5-gram jar of state-licensed flower from a Holyoke dispensary, and a 7 a.m. flight from Boston Logan to Atlanta-Hartsfield to visit her mother. As of April 28, 2026 — the effective date of the federal Schedule III rescheduling of state-licensed medical marijuana — Jane occupies a legal position that did not exist in March, and that the TSA agent who sees her bag at Logan, the airport police officer who would respond if cannabis is discovered there, and the Atlanta Police Department officer who might respond if she is referred at Hartsfield have not, between them, been formally briefed on.
Jane's question is the patient question this guide is here to answer: can a state-licensed medical marijuana patient fly with her medicine in 2026, and what is the realistic operational picture if she does?
The short, honest version is that the federal picture has changed and the practical picture has not changed nearly as much as the news coverage suggests. We will walk through what changed, who actually qualifies for the new federal posture, what to carry, the four common patient travel scenarios, and the parts of the federal landscape that did not move at all.
On April 27, 2026, the Transportation Security Administration updated the Medical Marijuana entry on its What Can I Bring? screening tool. The carry-on and checked-bag fields now read Yes (Special Instructions). The older page text declaring marijuana federally illegal is gone. The change tracked one day behind Acting Attorney General Todd Blanche's April 22 order moving two specific categories of marijuana into Schedule III: (1) FDA-approved cannabis-derived prescription drugs, and (2) state-licensed medical marijuana. The corresponding DEA Final Rule published in the Federal Register on April 28 and took effect that day. We have walked the news angle in our TSA Special Instructions explainer.
What the change does, for Jane: her Massachusetts-licensed flower is now, in principle, a Schedule III product when she walks through Logan TSA. The TSA page acknowledges that category exists. The page does not say what documentation she needs, what quantity she can carry, or what happens if the screener calls airport police.
What the change does not do: it does not preempt state law in Georgia. It does not create patient reciprocity. It does not give Jane a federal right to possess cannabis at Hartsfield. And on TSA's own account — an agency spokesperson told Snopes — the operational screening protocol has not actually changed. The page changed; the protocol did not.
Three documentary elements have to line up for a patient to fall inside the Schedule III carve-out, in the most-defensible reading of the order.
The patient needs to be registered with a state medical marijuana program — a card, a registry ID, or whatever formal credential the state issues. The credential needs to be current and (where the state allows mobile credentials) accessible at the checkpoint. A doctor's recommendation letter alone, in states that no longer use letters as the formal credential, is not enough.
The product needs to have been purchased from a state-licensed medical dispensary, in its original child-resistant packaging, with the dispensary label, batch identifier, and (where the state requires it) the patient's name intact. A vape cartridge transferred to an unlabeled case is not a documented Schedule III product. A gummy in a sandwich bag is not a documented Schedule III product. A jar of flower with the dispensary sticker peeled off is not a documented Schedule III product.
The state license under which the product was produced needs to be a qualifying medical-only license — or, in states with combined programs, the operator needs to have a defensible operational separation between its medical and adult-use sides. The patient-side proxy for this is buying from a medical-only dispensary or, in a combined program, presenting at the medical counter under the patient's medical credential.
A state license that authorizes both medical and adult-use activity does not, on the face of the DOJ order, qualify the medical activity for Schedule III; DEA has signaled it will look at operational separation rather than the paper of the license alone. From the patient's perspective, the safe posture is to buy under medical credentials, leave the product in original medical packaging, and keep the dispensary receipt showing a medical-channel transaction. Operators are working through the entity-segregation and registration mechanics on their side — see our two-tier federal cannabis market explainer for the operator-side picture.
If your prescriber has put you on Epidiolex, Marinol, Syndros, or Cesamet — the four FDA-approved cannabis-derived prescription drugs — air travel is straightforward and has always been. These products move in original pharmacy packaging with a pharmacy-printed label including patient name, drug name, dosage, prescriber, and pharmacy address. They are subject to TSA's general medication carry-on policy, which is well-documented and which screeners are trained to handle.
Pharmacy-labeled prescription liquids in excess of 3.4 ounces are exempt from the standard liquid rule for carry-on under TSA's medication policy. Epidiolex, in particular, ships in 100-milliliter pharmacy bottles, and the medication exemption applies. Bring the prescription, bring the pharmacy bottle, and budget an extra few minutes at the checkpoint to declare it.
The April rescheduling does not change handling for these products at the checkpoint. It does mean that the awkward prior framing — Schedule III prescription containing a Schedule I substance — is gone. The drug is straightforwardly Schedule III.
The TSA page now permits medical marijuana in both carry-on and checked baggage. The practical recommendation, for any patient who is going to fly with cannabis, is carry-on. Checked-bag cannabis is found in checked-bag screening by TSA, which is more thorough than carry-on screening and is conducted out of the passenger's presence. When TSA finds cannabis in checked baggage and refers it to airport police, the passenger learns about the referral at the destination — and is often unable to claim the bag or able to claim it only after a long conversation. Carry-on cannabis, by contrast, is in front of the passenger at the checkpoint, and the conversation that follows happens in real time.
For vape products, carry-on is not a preference — it is the FAA rule. Lithium-battery devices must travel in the cabin, never in checked baggage, with batteries protected from short-circuit. The cannabinoid content of a vape pen is downstream of the battery question; the battery question is what gets a checked bag pulled. See the FAA PackSafe entry on e-cigarettes.
The federal Schedule III change does not preempt state law. State and local police continue to enforce state criminal codes at the airport, and a federal Schedule III designation does not protect a traveler from arrest under, say, the Georgia Controlled Substances Act. Jane's Massachusetts card and her state-licensed Holyoke flower do not, on landing at Hartsfield, change her legal posture in Georgia at all. The patient card does not travel.
The patient-reciprocity picture for transport is grim. A handful of state programs allow visiting patients to purchase locally on a temporary card or to honor an out-of-state card for purchases inside the state — Hawaii, Maine, Nevada, New Hampshire, Oklahoma, and a few others do some version of this — but none of them allows a visiting patient to bring product across the state line. Patient reciprocity is about access at the destination, not about transport.
The destination-state question is the single biggest variable in patient travel. We have walked the airport-by-airport breakdown in our state-by-state airport enforcement guide; the short version is that LAX, SFO, OAK, ORD, MDW, LGA, JFK, BOS, SEA, DEN (with an airport-specific quirk), LAS, and PHX rarely arrest compliant adults, while ATL, DFW, IAH, MIA, MCO, CLT, BNA, BHM, JAN, OKC, and MEM treat possession as the state-law offense the state code defines it as.
The documentation list that gives a patient the best chance of a short checkpoint conversation:
The state-issued medical card or registry ID, current and verifiable. If your state uses a digital wallet pass, make sure your phone can pull it up without a cell signal. Some airports' security lanes are dead zones.
The product in its original child-resistant dispensary packaging with the dispensary label, batch identifier, and (where the state requires it) patient name intact. Do not transfer product to a different container to save space. Original packaging is the single most important documentary element.
The dispensary receipt showing a medical-channel transaction. A receipt with the patient's name on it is the cleanest version; even a receipt without the name still shows the medical channel and the date.
For FDA-approved cannabis pharmaceuticals: the original pharmacy bottle with the prescription label, plus a copy of the prescription. The prescription is not strictly required for TSA, but it answers any follow-up question instantly.
A photograph of the prescribing physician's recommendation letter, where the state still uses one. This is a belt-and-suspenders item; it is not a substitute for the card.
What not to bring, in any quantity, on a flight where there is any chance of state-law exposure on either end: anything in a personal grinder or smell-proof pouch without dispensary packaging. Anything decanted into travel containers. Anything bought from a recreational storefront if you are trying to rely on the Schedule III carve-out. Anything that was purchased without a receipt.
Scenario 1 — legal-program state to legal-program state (Boston to Los Angeles). Massachusetts patient with state card, Massachusetts-licensed flower in original packaging, flying BOS to LAX. The federal posture is Schedule III on both ends, post-April 28. The Massachusetts side has historically not arrested compliant adults at Logan; the California side operates under a written Los Angeles Airport Police Division policy that does not arrest adults 21 and over carrying compliant Prop 64 amounts (28.5 grams of flower, 8 grams of concentrate) at LAX. This scenario is, in practical terms, the lowest-friction patient-travel case in 2026. It was also the lowest-friction case before April 27.
Scenario 2 — legal-program state to prohibitionist state (Boston to Atlanta). Jane's scenario. The federal posture is Schedule III on the Boston side. Georgia is not a state that recognizes out-of-state medical cards; Georgia does not have an adult-use program; and ATL airport police enforce the Georgia Controlled Substances Code. Jane's Massachusetts card does not protect her in Georgia. If cannabis is found at Hartsfield and ATL APD is called, she is in the same legal position as any other adult in Georgia with cannabis — which is, depending on quantity, anywhere from a fine-and-release citation to a misdemeanor arrest.
The honest patient-travel advice for this scenario is: don't. Source product on the Georgia end, or accept that the trip is a non-medicating trip, or — if the medical need is real and pharmaceutical alternatives are available — bring an FDA-approved cannabis-derived prescription, which is unambiguously legal at both ends. The Schedule III change does not move this scenario at all.
Scenario 3 — non-program state to legal-program state (Birmingham to Denver). Patient flying from Birmingham (Alabama, no medical-marijuana program of the kind that creates qualifying state-issued patients in DOJ's reading) to Denver. The federal Schedule III carve-out does not, on the face of the order, cover this patient — there is no qualifying state-issued license on the Alabama side. Denver, on the destination side, has a quirk: Denver International Airport has its own airport-specific cannabis ban on all airport property (including pre-security), regardless of Colorado state law. A traveler who arrives at DEN with cannabis is in violation of DEN's airport policy even if Colorado state law would otherwise permit possession. The honest advice for this scenario is to fly without product and purchase compliantly at a Colorado adult-use dispensary after clearing the airport. Alabama's hemp/THCA position is its own complicated picture for the source-state question.
Scenario 4 — non-program state to non-program state (Birmingham to Charlotte). The federal Schedule III carve-out does not apply. Both states treat possession as a criminal-code matter. The TSA page change is irrelevant. Carry product on this flight at the same risk you would have carried it on the same flight in March.
The Schedule III rescheduling does not change Customs and Border Protection's posture at U.S. ports of entry. CBP enforces the Controlled Substances Act, treats both Schedule I marijuana and Farm Bill–compliant hemp as substances of interest, and has historically denied entry, issued lifetime bans, and seized product from travelers attempting to cross with cannabis in any form. International travel with any cannabis product — including a state medical card — remains an unforced-error category. Even Puerto Rico, despite being U.S. territory with a medical program, is a trap because the destination program does not recognize most mainland medical cards.
It does not change the Federal Aviation Administration's drug-testing rules for flight crew, ground crew with safety-sensitive functions, or air traffic controllers. It does not change federal-employee or DOT-regulated employee drug-testing rules. A patient who flies as a passenger with a Schedule III medical cannabis product can be a Schedule III patient on Monday and a fired pilot on Tuesday if she has a positive drug test in the interim.
It does not change international agreements. The 1961 Single Convention on Narcotic Drugs continues to constrain international air travel with cannabis even between two countries that have domestically legalized.
And it does not change hemp law. Hemp-derived CBD and Delta-9 products continue to be governed by the 2018 Farm Bill's 0.3-percent-by-dry-weight definition through November 11, 2026, when Section 781 of H.R. 5371 takes effect and replaces the dry-weight test with a 0.4-milligram-total-THC-per-container cap. For most patients, the hemp track is not the relevant track — but for patients who supplement state-licensed medical with over-the-counter hemp products, the November cliff is worth knowing about.
For most patients, the April 27 TSA page change makes the federal picture cleaner without changing the practical picture much. A patient flying with state-licensed medical cannabis from one program-recognizing state to another, in original packaging, with a card and a receipt, is in a marginally better position than she was on April 26 — mostly because the TSA page no longer formally tells the screener to treat her medicine as federal contraband. A patient flying to a prohibitionist destination is in the same position she was in March: the state-law calculus is what matters, the patient card does not travel, and the right move is usually to not bring product.
The June 29 DEA hearing on broader rescheduling is the next domino. If it succeeds, the TSA picture eventually gets simpler. If it stalls, the current two-tier split is permanent. Patients planning travel between now and Q4 should plan around the picture as it sits, not as it might.
If a checkpoint or destination-airport conversation goes wrong and state law is on the table, get state-specific representation. Our Cannabis Lawyer Directory indexes attorneys by state.
This guide is editorial and does not constitute legal or medical advice. State and federal cannabis law moves quickly; verify any specific question with counsel admitted in the relevant jurisdiction.
Last updated: May 23, 2026 · By Compliance Carl, Senior Compliance Editor
Jane is a Massachusetts medical marijuana patient. She has a state-issued card, a 3.5-gram jar of state-licensed flower from a Holyoke dispensary, and a 7 a.m. flight from Boston Logan to Atlanta-Hartsfield to visit her mother. As of April 28, 2026 — the effective date of the federal Schedule III rescheduling of state-licensed medical marijuana — Jane occupies a legal position that did not exist in March, and that the TSA agent who sees her bag at Logan, the airport police officer who would respond if cannabis is discovered there, and the Atlanta Police Department officer who might respond if she is referred at Hartsfield have not, between them, been formally briefed on.
Jane's question is the patient question this guide is here to answer: can a state-licensed medical marijuana patient fly with her medicine in 2026, and what is the realistic operational picture if she does?
The short, honest version is that the federal picture has changed and the practical picture has not changed nearly as much as the news coverage suggests. We will walk through what changed, who actually qualifies for the new federal posture, what to carry, the four common patient travel scenarios, and the parts of the federal landscape that did not move at all.
On April 27, 2026, the Transportation Security Administration updated the Medical Marijuana entry on its What Can I Bring? screening tool. The carry-on and checked-bag fields now read Yes (Special Instructions). The older page text declaring marijuana federally illegal is gone. The change tracked one day behind Acting Attorney General Todd Blanche's April 22 order moving two specific categories of marijuana into Schedule III: (1) FDA-approved cannabis-derived prescription drugs, and (2) state-licensed medical marijuana. The corresponding DEA Final Rule published in the Federal Register on April 28 and took effect that day. We have walked the news angle in our TSA Special Instructions explainer.
What the change does, for Jane: her Massachusetts-licensed flower is now, in principle, a Schedule III product when she walks through Logan TSA. The TSA page acknowledges that category exists. The page does not say what documentation she needs, what quantity she can carry, or what happens if the screener calls airport police.
What the change does not do: it does not preempt state law in Georgia. It does not create patient reciprocity. It does not give Jane a federal right to possess cannabis at Hartsfield. And on TSA's own account — an agency spokesperson told Snopes — the operational screening protocol has not actually changed. The page changed; the protocol did not.
Three documentary elements have to line up for a patient to fall inside the Schedule III carve-out, in the most-defensible reading of the order.
The patient needs to be registered with a state medical marijuana program — a card, a registry ID, or whatever formal credential the state issues. The credential needs to be current and (where the state allows mobile credentials) accessible at the checkpoint. A doctor's recommendation letter alone, in states that no longer use letters as the formal credential, is not enough.
The product needs to have been purchased from a state-licensed medical dispensary, in its original child-resistant packaging, with the dispensary label, batch identifier, and (where the state requires it) the patient's name intact. A vape cartridge transferred to an unlabeled case is not a documented Schedule III product. A gummy in a sandwich bag is not a documented Schedule III product. A jar of flower with the dispensary sticker peeled off is not a documented Schedule III product.
The state license under which the product was produced needs to be a qualifying medical-only license — or, in states with combined programs, the operator needs to have a defensible operational separation between its medical and adult-use sides. The patient-side proxy for this is buying from a medical-only dispensary or, in a combined program, presenting at the medical counter under the patient's medical credential.
A state license that authorizes both medical and adult-use activity does not, on the face of the DOJ order, qualify the medical activity for Schedule III; DEA has signaled it will look at operational separation rather than the paper of the license alone. From the patient's perspective, the safe posture is to buy under medical credentials, leave the product in original medical packaging, and keep the dispensary receipt showing a medical-channel transaction. Operators are working through the entity-segregation and registration mechanics on their side — see our two-tier federal cannabis market explainer for the operator-side picture.
If your prescriber has put you on Epidiolex, Marinol, Syndros, or Cesamet — the four FDA-approved cannabis-derived prescription drugs — air travel is straightforward and has always been. These products move in original pharmacy packaging with a pharmacy-printed label including patient name, drug name, dosage, prescriber, and pharmacy address. They are subject to TSA's general medication carry-on policy, which is well-documented and which screeners are trained to handle.
Pharmacy-labeled prescription liquids in excess of 3.4 ounces are exempt from the standard liquid rule for carry-on under TSA's medication policy. Epidiolex, in particular, ships in 100-milliliter pharmacy bottles, and the medication exemption applies. Bring the prescription, bring the pharmacy bottle, and budget an extra few minutes at the checkpoint to declare it.
The April rescheduling does not change handling for these products at the checkpoint. It does mean that the awkward prior framing — Schedule III prescription containing a Schedule I substance — is gone. The drug is straightforwardly Schedule III.
The TSA page now permits medical marijuana in both carry-on and checked baggage. The practical recommendation, for any patient who is going to fly with cannabis, is carry-on. Checked-bag cannabis is found in checked-bag screening by TSA, which is more thorough than carry-on screening and is conducted out of the passenger's presence. When TSA finds cannabis in checked baggage and refers it to airport police, the passenger learns about the referral at the destination — and is often unable to claim the bag or able to claim it only after a long conversation. Carry-on cannabis, by contrast, is in front of the passenger at the checkpoint, and the conversation that follows happens in real time.
For vape products, carry-on is not a preference — it is the FAA rule. Lithium-battery devices must travel in the cabin, never in checked baggage, with batteries protected from short-circuit. The cannabinoid content of a vape pen is downstream of the battery question; the battery question is what gets a checked bag pulled. See the FAA PackSafe entry on e-cigarettes.
The federal Schedule III change does not preempt state law. State and local police continue to enforce state criminal codes at the airport, and a federal Schedule III designation does not protect a traveler from arrest under, say, the Georgia Controlled Substances Act. Jane's Massachusetts card and her state-licensed Holyoke flower do not, on landing at Hartsfield, change her legal posture in Georgia at all. The patient card does not travel.
The patient-reciprocity picture for transport is grim. A handful of state programs allow visiting patients to purchase locally on a temporary card or to honor an out-of-state card for purchases inside the state — Hawaii, Maine, Nevada, New Hampshire, Oklahoma, and a few others do some version of this — but none of them allows a visiting patient to bring product across the state line. Patient reciprocity is about access at the destination, not about transport.
The destination-state question is the single biggest variable in patient travel. We have walked the airport-by-airport breakdown in our state-by-state airport enforcement guide; the short version is that LAX, SFO, OAK, ORD, MDW, LGA, JFK, BOS, SEA, DEN (with an airport-specific quirk), LAS, and PHX rarely arrest compliant adults, while ATL, DFW, IAH, MIA, MCO, CLT, BNA, BHM, JAN, OKC, and MEM treat possession as the state-law offense the state code defines it as.
The documentation list that gives a patient the best chance of a short checkpoint conversation:
The state-issued medical card or registry ID, current and verifiable. If your state uses a digital wallet pass, make sure your phone can pull it up without a cell signal. Some airports' security lanes are dead zones.
The product in its original child-resistant dispensary packaging with the dispensary label, batch identifier, and (where the state requires it) patient name intact. Do not transfer product to a different container to save space. Original packaging is the single most important documentary element.
The dispensary receipt showing a medical-channel transaction. A receipt with the patient's name on it is the cleanest version; even a receipt without the name still shows the medical channel and the date.
For FDA-approved cannabis pharmaceuticals: the original pharmacy bottle with the prescription label, plus a copy of the prescription. The prescription is not strictly required for TSA, but it answers any follow-up question instantly.
A photograph of the prescribing physician's recommendation letter, where the state still uses one. This is a belt-and-suspenders item; it is not a substitute for the card.
What not to bring, in any quantity, on a flight where there is any chance of state-law exposure on either end: anything in a personal grinder or smell-proof pouch without dispensary packaging. Anything decanted into travel containers. Anything bought from a recreational storefront if you are trying to rely on the Schedule III carve-out. Anything that was purchased without a receipt.
Scenario 1 — legal-program state to legal-program state (Boston to Los Angeles). Massachusetts patient with state card, Massachusetts-licensed flower in original packaging, flying BOS to LAX. The federal posture is Schedule III on both ends, post-April 28. The Massachusetts side has historically not arrested compliant adults at Logan; the California side operates under a written Los Angeles Airport Police Division policy that does not arrest adults 21 and over carrying compliant Prop 64 amounts (28.5 grams of flower, 8 grams of concentrate) at LAX. This scenario is, in practical terms, the lowest-friction patient-travel case in 2026. It was also the lowest-friction case before April 27.
Scenario 2 — legal-program state to prohibitionist state (Boston to Atlanta). Jane's scenario. The federal posture is Schedule III on the Boston side. Georgia is not a state that recognizes out-of-state medical cards; Georgia does not have an adult-use program; and ATL airport police enforce the Georgia Controlled Substances Code. Jane's Massachusetts card does not protect her in Georgia. If cannabis is found at Hartsfield and ATL APD is called, she is in the same legal position as any other adult in Georgia with cannabis — which is, depending on quantity, anywhere from a fine-and-release citation to a misdemeanor arrest.
The honest patient-travel advice for this scenario is: don't. Source product on the Georgia end, or accept that the trip is a non-medicating trip, or — if the medical need is real and pharmaceutical alternatives are available — bring an FDA-approved cannabis-derived prescription, which is unambiguously legal at both ends. The Schedule III change does not move this scenario at all.
Scenario 3 — non-program state to legal-program state (Birmingham to Denver). Patient flying from Birmingham (Alabama, no medical-marijuana program of the kind that creates qualifying state-issued patients in DOJ's reading) to Denver. The federal Schedule III carve-out does not, on the face of the order, cover this patient — there is no qualifying state-issued license on the Alabama side. Denver, on the destination side, has a quirk: Denver International Airport has its own airport-specific cannabis ban on all airport property (including pre-security), regardless of Colorado state law. A traveler who arrives at DEN with cannabis is in violation of DEN's airport policy even if Colorado state law would otherwise permit possession. The honest advice for this scenario is to fly without product and purchase compliantly at a Colorado adult-use dispensary after clearing the airport. Alabama's hemp/THCA position is its own complicated picture for the source-state question.
Scenario 4 — non-program state to non-program state (Birmingham to Charlotte). The federal Schedule III carve-out does not apply. Both states treat possession as a criminal-code matter. The TSA page change is irrelevant. Carry product on this flight at the same risk you would have carried it on the same flight in March.
The Schedule III rescheduling does not change Customs and Border Protection's posture at U.S. ports of entry. CBP enforces the Controlled Substances Act, treats both Schedule I marijuana and Farm Bill–compliant hemp as substances of interest, and has historically denied entry, issued lifetime bans, and seized product from travelers attempting to cross with cannabis in any form. International travel with any cannabis product — including a state medical card — remains an unforced-error category. Even Puerto Rico, despite being U.S. territory with a medical program, is a trap because the destination program does not recognize most mainland medical cards.
It does not change the Federal Aviation Administration's drug-testing rules for flight crew, ground crew with safety-sensitive functions, or air traffic controllers. It does not change federal-employee or DOT-regulated employee drug-testing rules. A patient who flies as a passenger with a Schedule III medical cannabis product can be a Schedule III patient on Monday and a fired pilot on Tuesday if she has a positive drug test in the interim.
It does not change international agreements. The 1961 Single Convention on Narcotic Drugs continues to constrain international air travel with cannabis even between two countries that have domestically legalized.
And it does not change hemp law. Hemp-derived CBD and Delta-9 products continue to be governed by the 2018 Farm Bill's 0.3-percent-by-dry-weight definition through November 11, 2026, when Section 781 of H.R. 5371 takes effect and replaces the dry-weight test with a 0.4-milligram-total-THC-per-container cap. For most patients, the hemp track is not the relevant track — but for patients who supplement state-licensed medical with over-the-counter hemp products, the November cliff is worth knowing about.
For most patients, the April 27 TSA page change makes the federal picture cleaner without changing the practical picture much. A patient flying with state-licensed medical cannabis from one program-recognizing state to another, in original packaging, with a card and a receipt, is in a marginally better position than she was on April 26 — mostly because the TSA page no longer formally tells the screener to treat her medicine as federal contraband. A patient flying to a prohibitionist destination is in the same position she was in March: the state-law calculus is what matters, the patient card does not travel, and the right move is usually to not bring product.
The June 29 DEA hearing on broader rescheduling is the next domino. If it succeeds, the TSA picture eventually gets simpler. If it stalls, the current two-tier split is permanent. Patients planning travel between now and Q4 should plan around the picture as it sits, not as it might.
If a checkpoint or destination-airport conversation goes wrong and state law is on the table, get state-specific representation. Our Cannabis Lawyer Directory indexes attorneys by state.
This guide is editorial and does not constitute legal or medical advice. State and federal cannabis law moves quickly; verify any specific question with counsel admitted in the relevant jurisdiction.
